Bank of America Lowers PO On Amylin Pharmaceuticals To $15

August 8, 2011 6:59 AM | 8 seconds read |
Bank of America has lowered the price objective on Amylin Pharmaceuticals AMLN from $16 to $15 and maintains its Neutral rating.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Price TargetAnalyst RatingsBank of AmericaBiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!